台新藥 (6838.TW) 2025Q3 financial report shows revenue of 911K TWD, with a YoY growth rate of -78.98%. This clearly indicates that 台新藥 (6838.TW) is facing severe revenue challenges and a significant deterioration. To better understand the business situation, investors are advised to look beyond the revenue YoY, and closely examine trends in net profit, operating profit, and gross margin. In addition, leveraging third-party data such as Growin AI Value Analysis will provide a more comprehensive assessment of the operational pressure and potential financial risks faced by 台新藥 (6838.TW).